Phase I, Safety and Immunogenicity of Gardasil in Systemic Lupus Erythematosus

Trial Profile

Phase I, Safety and Immunogenicity of Gardasil in Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Acronyms GARDASIL
  • Most Recent Events

    • 21 Apr 2017 Status changed from active, no longer recruiting to completed, according to the results published in the Vaccine.
    • 09 Apr 2017 Results evaluating the safety and immunogenicity published in the Vaccine.
    • 08 Jun 2015 Planned End Date changed from 1 May 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top